Autoimmune Disease Management
Expert-defined terms from the Professional Certificate in Autoimmune Disease Advocacy course at LearnUNI. Free to read, free to share, paired with a professional course.
ABAT – Autoimmune Baseline Assessment Tool #
Baseline labs, disease activity index. A structured questionnaire and lab panel used at diagnosis to establish patient’s initial disease status. Example: clinicians use ABAT to compare longitudinal changes. Challenge: ensuring completeness across diverse healthcare settings.
ACE Inhibitors – Angiotensin‑Converting Enzyme inhibitors #
RAAS blockers, antihypertensives. Medications that may modulate immune response by reducing inflammatory cytokine release. Practical application: prescribed for patients with lupus nephritis to control blood pressure. Challenge: rare cases of drug‑induced autoimmunity.
ADCC – Antibody‑Dependent Cellular Cytotoxicity #
Fc‑mediated killing, immune effector function. A mechanism by which therapeutic antibodies recruit NK cells to destroy target cells. Example: rituximab leverages ADCC to deplete B‑cells in rheumatoid arthritis. Challenge: variability in patient FcγR polymorphisms affecting efficacy.
ADA – Anti‑Drug Antibodies #
Immunogenicity, neutralizing antibodies. Host‑generated antibodies that bind to biologic therapies, potentially reducing drug effectiveness. Practical application: monitoring ADA levels in patients on TNF inhibitors. Challenge: distinguishing clinically relevant ADA from low‑titer, non‑impactful antibodies.
AID – Autoimmune Disease #
Chronic inflammation, autoimmunity. A condition in which the immune system mistakenly attacks self‑tissues. Example: multiple sclerosis is an AID affecting the central nervous system. Challenge: heterogeneity of presentation complicates standardized management.
ALD – Autoimmune Liver Disease #
Autoimmune hepatitis, primary biliary cholangitis. Chronic liver disorders characterized by immune‑mediated hepatocyte injury. Practical application: corticosteroid therapy to suppress hepatic inflammation. Challenge: balancing immunosuppression with infection risk.
ANA – Antinuclear Antibody #
Autoantibody panel, screening test. Serum antibodies directed against nuclear components, often positive in systemic autoimmune conditions. Example: a speckled ANA pattern suggests mixed connective tissue disease. Challenge: false‑positive results in healthy individuals leading to over‑investigation.
APC – Antigen‑Presenting Cell #
Dendritic cell, macrophage. Cells that process and present antigens to T‑cells, initiating adaptive immunity. Practical application: dendritic cell vaccines being explored for tolerance induction in type 1 diabetes. Challenge: ensuring targeted delivery without systemic activation.
APS – Antiphospholipid Syndrome #
Thrombosis, lupus anticoagulant. An autoimmune hypercoagulable state marked by antiphospholipid antibodies. Example: recurrent miscarriages in a patient with systemic lupus erythematosus. Challenge: long‑term anticoagulation management and monitoring for bleeding.
ASCT – Autologous Stem Cell Transplant #
Hematopoietic rescue, high‑dose therapy. Procedure where a patient’s own stem cells are harvested, high‑dose immunosuppression administered, then cells reinfused. Practical application: used in severe refractory multiple sclerosis. Challenge: transplant‑related morbidity and cost.
ASD – Autoimmune Serology Dashboard #
Laboratory panel, disease monitoring. An integrated digital interface aggregating autoantibody results for longitudinal tracking. Example: clinicians view ANA, ENA, RF trends on a single screen. Challenge: data interoperability across laboratory information systems.
ATG – Anti‑Thymocyte Globulin #
Polyclonal antibodies, lymphocyte depletion. Immunosuppressive agent used to deplete T‑cells in severe autoimmune flares. Practical application: induction therapy for severe lupus nephritis. Challenge: heightened infection susceptibility and cytokine release syndrome.
AVD – Autoimmune Disease Activity Score #
SLEDAI, DAS28. Composite numeric index quantifying disease activity based on clinical and laboratory parameters. Example: a DAS28 score >5.1 indicates high activity in rheumatoid arthritis. Challenge: subjectivity of patient‑reported components.
BAFF – B‑Cell Activating Factor #
TNFSF13B, BLyS. Cytokine promoting B‑cell survival and differentiation; elevated in many AIDs. Practical application: belimumab targets BAFF to reduce autoantibody production in systemic lupus. Challenge: incomplete inhibition may leave residual disease activity.
BCDT – B‑Cell Depleting Therapy #
Rituximab, ocrelizumab. Therapeutic approach that eliminates CD20‑positive B‑cells to diminish autoantibody generation. Example: rituximab used off‑label for Sjögren’s syndrome. Challenge: delayed B‑cell repopulation leading to prolonged immunosuppression.
BIOMARKER – Biological Marker #
Predictive, prognostic indicator. Measurable substance indicating disease presence, severity, or therapeutic response. Practical application: serum IL‑6 levels predict response to tocilizumab in rheumatoid arthritis. Challenge: establishing validated cutoff values across populations.
BLM – Baseline Laboratory Monitoring #
CBC, CMP, ESR. Routine pre‑treatment tests to assess organ function and inflammatory status. Example: baseline liver enzymes before initiating methotrexate. Challenge: patient adherence to repeat monitoring schedules.
BM – Bone Marrow #
Hematopoiesis, niche. Primary site of blood cell production; can be targeted in hematologic autoimmune disorders. Practical application: bone‑marrow biopsy to rule out lymphoma masquerading as autoimmune disease. Challenge: invasive nature limits frequent assessment.
BRM – Biologic Response Modifier #
Monoclonal antibody, fusion protein. Category of agents that modify immune pathways, such as TNF inhibitors. Example: etanercept is a BRM used in psoriatic arthritis. Challenge: immunogenicity leading to loss of response.
CARD – Clinical Autoimmune Risk Determinant #
Genetic susceptibility, environmental trigger. Composite score estimating an individual’s likelihood of developing an autoimmune condition. Practical application: counseling patients with family history of type 1 diabetes. Challenge: limited predictive power without longitudinal validation.
CCF – Complement Component Factor #
C3, C4, CH50. Serum proteins involved in innate immunity; low levels often reflect consumption in active disease. Example: depressed C4 in active lupus. Challenge: complement levels can be influenced by infections, confounding interpretation.
CD4 – Cluster of Differentiation 4 #
T‑helper cells, immune regulation. Subset of T‑cells that orchestrate immune responses; central in autoimmunity pathogenesis. Practical application: measuring CD4 counts to gauge immune competence in patients on high‑dose steroids. Challenge: CD4 fluctuations may not correlate directly with disease activity.
CD8 – Cluster of Differentiation 8 #
Cytotoxic T‑cells, viral immunity. Lymphocytes that kill infected or aberrant cells; implicated in tissue destruction in autoimmune neuropathies. Example: CD8‑mediated axonal loss in multiple sclerosis lesions. Challenge: targeting CD8 without compromising antiviral defense.
CID – Chronic Inflammatory Disease #
Autoimmune, non‑infectious. Long‑standing condition characterized by persistent inflammation. Practical application: using disease‑modifying antirheumatic drugs (DMARDs) to control CID activity. Challenge: distinguishing CID flare from superimposed infection.
CLIA – Clinical Laboratory Improvement Amendments #
Regulatory standards, quality control. Federal standards ensuring reliability of laboratory testing. Example: autoantibody assays must meet CLIA certification. Challenge: small clinics may struggle with compliance costs.
CMP – Comprehensive Metabolic Panel #
Renal function, electrolytes, glucose. Blood test suite used to monitor organ toxicity from immunosuppressants. Practical application: checking creatinine before initiating cyclosporine. Challenge: interpreting mild abnormalities in the context of disease activity.
CRP – C‑Reactive Protein #
Acute‑phase reactant, inflammation marker. Protein whose serum concentration rises rapidly during systemic inflammation. Example: elevated CRP predicts flare in rheumatoid arthritis. Challenge: CRP can be elevated by infection, reducing disease‑specific specificity.
CTLA‑4 – Cytotoxic T‑Lymphocyte‑Associated Protein 4 #
Immune checkpoint, T‑cell regulator. Inhibitory receptor that down‑regulates immune activation; therapeutic target in autoimmune modulation. Practical application: abatacept mimics CTLA‑4 to dampen T‑cell activity in rheumatoid arthritis. Challenge: risk of opportunistic infections due to broad immune suppression.
CXCL13 – C‑X‑C Motif Chemokine Ligand 13 #
B‑cell chemoattractant, germinal centre. Chemokine involved in B‑cell trafficking; elevated levels correlate with disease activity in lupus. Example: serum CXCL13 used as a biomarker for renal flare. Challenge: assay standardization across laboratories.
DAS28 – Disease Activity Score using 28 joint counts #
Rheumatoid arthritis, composite index. Numeric score integrating tender/swollen joint counts, ESR/CRP, and patient global assessment. Practical application: guiding treatment escalation when DAS28 >5.1. Challenge: may underestimate disease in patients with extra‑articular manifestations.
DC – Dendritic Cell #
Antigen presentation, tolerance induction. Professional antigen‑presenting cells that bridge innate and adaptive immunity. Practical application: tolerogenic DCs being explored to re‑educate immune system in type 1 diabetes. Challenge: ensuring stability of tolerogenic phenotype in vivo.
DMARD – Disease‑Modifying Antirheumatic Drug #
Conventional, biologic, targeted synthetic. Class of agents that alter disease course rather than merely relieve symptoms. Example: methotrexate as first‑line DMARD in rheumatoid arthritis. Challenge: delayed onset of action requiring bridging with NSAIDs or steroids.
DNA‑sequestration – Therapeutic strategy to bind extracellular DNA #
NET inhibition, immunogenic debris. Use of agents like DNase to degrade neutrophil extracellular traps (NETs) implicated in vasculitis. Practical application: inhaled DNase in systemic lupus‑related pulmonary disease. Challenge: limited efficacy in established organ damage.
EBV – Epstein‑Barr Virus #
Herpesvirus, latent infection. Viral pathogen implicated in triggering autoimmunity through molecular mimicry. Example: elevated EBV viral load observed in patients with multiple sclerosis. Challenge: no definitive antiviral strategy to prevent autoimmune initiation.
EHR – Electronic Health Record #
Digital chart, data repository. System used to capture patient encounters, labs, and medication histories. Practical application: integrating disease activity scores into the EHR for real‑time decision support. Challenge: interoperability between disparate EHR platforms.
ELISA – Enzyme‑Linked Immunosorbent Assay #
Quantitative immunoassay, serology. Laboratory technique to measure specific antibodies or antigens. Example: ELISA used to quantify anti‑dsDNA antibodies in lupus monitoring. Challenge: cross‑reactivity may produce false‑positive results.
ENA – Extractable Nuclear Antigen panel #
Autoantibody profiling, specificity. Group of autoantibodies (e.g., Ro, La, Sm) aiding in diagnosis of systemic autoimmune diseases. Practical application: distinguishing Sjögren’s from systemic lupus based on Ro/La positivity. Challenge: limited sensitivity for early disease.
EULAR – European League Against Rheumatism #
Guideline body, professional society. Organization that publishes consensus treatment recommendations for rheumatic and musculoskeletal diseases. Example: 2023 EULAR guideline for systemic lupus management. Challenge: translating guidelines into resource‑limited settings.
FAIR – Findable, Accessible, Interoperable, Reusable #
Data principles, research transparency. Framework for managing research data, including autoimmunity datasets. Practical application: depositing biomarker datasets in FAIR repositories to enable meta‑analysis. Challenge: ensuring patient privacy while maintaining openness.
FCGR – Fc‑Gamma Receptor #
IgG binding, immune activation. Cell surface receptors that mediate antibody‑dependent cellular cytotoxicity. Example: polymorphisms in FCGR3A influence response to rituximab. Challenge: genetic testing not routinely available in clinical practice.
FLS – Fibroblast‑Like Synoviocyte #
Joint pathology, pannus formation. Aggressive mesenchymal cells contributing to cartilage destruction in rheumatoid arthritis. Practical application: targeting FLS signaling pathways with novel small‑molecule inhibitors. Challenge: achieving selectivity without affecting normal fibroblasts.
GC – Glucocorticoid #
Corticosteroid, anti‑inflammatory. Hormone class widely used to suppress acute autoimmune inflammation. Example: prednisone taper in a lupus flare. Challenge: long‑term adverse effects such as osteoporosis and hyperglycemia.
GIA – Glucose‑Insulin Autoantibody #
Type 1 diabetes marker, serology. Autoantibody directed against insulin or related antigens, indicating autoimmune beta‑cell destruction. Practical application: screening high‑risk children for early intervention. Challenge: low‑titer antibodies may be transient.
HLA – Human Leukocyte Antigen #
MHC, genetic susceptibility. Gene complex encoding cell‑surface proteins essential for antigen presentation; certain alleles confer autoimmune risk. Example: HLA‑DRB1*04 associated with rheumatoid arthritis. Challenge: complex linkage disequilibrium complicates risk modeling.
HSCT – Hematopoietic Stem Cell Transplant #
Allogeneic, immune reset. Transplantation of donor stem cells to reconstitute a tolerant immune system. Practical application: used in severe refractory systemic sclerosis. Challenge: graft‑versus‑host disease and high procedural cost.
IAI – Immune‑Associated Inflammation #
Autoimmune, cytokine storm. Term describing inflammation driven primarily by dysregulated immune pathways rather than infection. Example: cytokine release syndrome after CAR‑T therapy mimics IAI. Challenge: differentiating IAI from septic inflammation.
IBD – Inflammatory Bowel Disease #
Crohn’s disease, ulcerative colitis. Chronic gastrointestinal disorders with autoimmune components. Practical application: biologic agents (e.g., infliximab) targeting TNF‑α improve mucosal healing. Challenge: loss of response due to antibody formation.
ICD‑10 – International Classification of Diseases, 10th Revision #
Diagnostic coding, billing. Standardized coding system used to document autoimmune diagnoses for reimbursement and epidemiology. Example: code M32 for systemic lupus erythematosus. Challenge: coding accuracy affects data quality for research.
IFN‑γ – Interferon‑Gamma #
Th1 cytokine, macrophage activation. Pro‑inflammatory cytokine implicated in organ‑specific autoimmunity such as type 1 diabetes. Practical application: IFN‑γ blockade under investigation for autoimmune uveitis. Challenge: inhibition may predispose to intracellular infections.
IL‑6 – Interleukin‑6 #
Acute‑phase cytokine, B‑cell growth factor. Central mediator of systemic inflammation; target of tocilizumab. Example: IL‑6 levels correlate with disease activity in rheumatoid arthritis. Challenge: monitoring for elevated liver enzymes and lipid abnormalities during therapy.
IL‑17 – Interleukin‑17 #
Th17 cytokine, neutrophil recruitment. Promotes inflammation in psoriasis and ankylosing spondylitis. Practical application: secukinumab inhibits IL‑17A, reducing skin lesions. Challenge: increased risk of candidiasis due to impaired mucosal immunity.
IL‑23 – Interleukin‑23 #
Th17 axis, cytokine network. Supports survival of IL‑17‑producing cells; therapeutic target in psoriatic disease. Example: ustekinumab blocks IL‑12/23, improving joint symptoms. Challenge: cost and need for long‑term safety data.
IMD – Immune‑Mediated Disease #
Autoimmunity, hypersensitivity. Broad term encompassing conditions where immune mechanisms cause tissue injury. Practical application: using immunomodulatory strategies across disease categories. Challenge: heterogeneity hinders uniform therapeutic algorithms.
IMMUNOGLOBULIN – Intravenous Immunoglobulin (IVIG) #
Immunomodulation, antibody replacement. Pooled IgG administered to modulate autoantibody activity and provide passive immunity. Example: high‑dose IVIG used in Guillain‑Barré syndrome. Challenge: limited supply and high cost.
INFLIXIMAB – Chimeric anti‑TNF‑α monoclonal antibody #
Biologic, TNF blockade. Used to control inflammation in Crohn’s disease, rheumatoid arthritis, and psoriasis. Practical application: induction dosing followed by maintenance infusions. Challenge: formation of anti‑drug antibodies reducing long‑term efficacy.
JAK – Janus Kinase #
Signal transduction, cytokine pathway. Intracellular enzymes mediating cytokine receptor signaling; target of small‑molecule inhibitors. Example: tofacitinib inhibits JAK1/3, approved for ulcerative colitis. Challenge: monitoring for herpes zoster reactivation and lipid changes.
KIR – Killer‑Immunoglobulin‑Like Receptor #
NK cell regulation, genetic diversity. Receptors that modulate natural killer cell activity; certain KIR‑HLA combinations influence autoimmunity risk. Practical application: research into KIR typing for personalized therapy. Challenge: complex genotype‑phenotype relationships.
LDH – Lactate Dehydrogenase #
Cellular injury marker, enzymatic assay. Enzyme released from damaged cells; elevated in hemolytic anemia and active lupus. Example: rising LDH may signal a flare of autoimmune hemolytic anemia. Challenge: nonspecific elevation limits diagnostic precision.
LEF – Leflunomide #
DMARD, pyrimidine synthesis inhibitor. Oral immunosuppressant that inhibits dihydroorotate dehydrogenase, reducing lymphocyte proliferation. Practical application: maintenance therapy in rheumatoid arthritis after methotrexate failure. Challenge: hepatotoxicity requiring regular liver function monitoring.
LIC – Lupus Interstitial Cystitis #
Autoimmune bladder inflammation, chronic pelvic pain. Overlap syndrome where systemic lupus contributes to bladder irritation. Example: patients present with dysuria and sterile urine cultures. Challenge: limited evidence for specific therapies beyond standard lupus management.
LMWH – Low‑Molecular‑Weight Heparin #
Anticoagulant, thrombosis prophylaxis. Preferred anticoagulant in antiphospholipid syndrome due to predictable pharmacokinetics. Practical application: subcutaneous enoxaparin for pregnant patients with APS. Challenge: dose adjustment in renal impairment.
mAb – Monoclonal Antibody #
Biologic, targeted therapy. Laboratory‑produced antibody designed to bind a specific antigen. Example: adalimumab binds TNF‑α, used in multiple autoimmune conditions. Challenge: high manufacturing cost and need for cold chain logistics.
MEFV – Mediterranean Fever Gene #
Familial Mediterranean fever, pyrin mutation. Gene whose mutations cause autoinflammatory attacks; sometimes overlap with autoimmune phenotypes. Practical application: colchicine therapy to prevent attacks. Challenge: variable penetrance complicates genetic counseling.
MHCI – Major Histocompatibility Complex Class I #
Antigen presentation, CD8⁺ T‑cell activation. Molecules presenting endogenous peptides; certain alleles linked to autoimmune susceptibility. Example: HLA‑B27 association with ankylosing spondylitis. Challenge: many alleles, making risk stratification complex.
MMR – Malignant Melanoma Registry (used in autoimmunity research) #
Data collection, outcome tracking. Repository for patients with overlapping autoimmune and oncologic conditions. Practical application: analyzing immunotherapy‑related autoimmune adverse events. Challenge: ensuring standardized data capture across centers.
MRP – Medication Review Protocol #
Pharmacovigilance, deprescribing. Structured process for evaluating patient medication lists to reduce polypharmacy. Example: using MRP to identify unnecessary NSAIDs in chronic arthritis. Challenge: time constraints in busy clinical settings.
MS – Multiple Sclerosis #
Central nervous system autoimmunity, demyelination. Chronic disease characterized by immune‑mediated attack on myelin. Practical application: disease‑modifying therapies such as fingolimod to reduce relapse rate. Challenge: balancing efficacy with infection risk, especially in older patients.
MTX – Methotrexate #
First‑line DMARD, antifolate. Oral or subcutaneous agent inhibiting dihydrofolate reductase, reducing immune cell proliferation. Example: weekly dosing in rheumatoid arthritis. Challenge: gastrointestinal intolerance and hepatic toxicity requiring folic acid supplementation and monitoring.
NAFLD – Non‑Alcoholic Fatty Liver Disease #
Metabolic liver injury, autoimmune overlap. Condition that may coexist with autoimmune hepatitis, complicating management. Practical application: lifestyle modification alongside immunosuppression. Challenge: distinguishing hepatic flare from metabolic steatosis on imaging.
NB‑LADS – Neurologic‑Based Lupus Activity Disease Score #
Neuro‑SLE assessment, composite index. Tool integrating neuro‑cognitive testing, MRI findings, and serology for lupus patients with CNS involvement. Example: score guides escalation to cyclophosphamide. Challenge: limited validation in diverse populations.
NCBI – National Center for Biotechnology Information #
Database, literature repository. Source for gene, protein, and disease information used by clinicians researching autoimmunity. Practical application: accessing PubMed for latest therapeutic trials. Challenge: information overload without curated summaries.
NEUT – Neutrophil #
Innate immune cell, NET formation. First‑line responders that can release extracellular traps contributing to vascular injury in autoimmune vasculitis. Practical application: measuring neutrophil‑to‑lymphocyte ratio as a flare marker. Challenge: ratio can be altered by infection or stress.
NMOSD – Neuromyelitis Optica Spectrum Disorder #
Aquaporin‑4 autoimmunity, CNS demyelination. Autoimmune condition distinct from multiple sclerosis, characterized by optic neuritis and longitudinal spinal lesions. Example: rituximab reduces relapse frequency. Challenge: diagnostic delay due to overlapping symptoms.
NSAID – Non‑Steroidal Anti‑Inflammatory Drug #
Pain relief, COX inhibition. Common symptomatic treatment for arthritis and other inflammatory pain. Practical application: ibuprofen as bridge therapy while DMARDs take effect. Challenge: gastrointestinal ulcer risk, especially with steroids.
ODC – Oral Disease Control #
Self‑management, patient education. Program encouraging patients to track symptoms, medication adherence, and lifestyle factors. Example: smartphone app prompts daily joint pain scores. Challenge: sustained patient engagement over long disease course.
OMIM – Online Mendelian Inheritance in Man #
Genetic database, phenotype catalog. Resource detailing gene‑disease relationships, useful for identifying autoimmune susceptibility loci. Practical application: referencing HLA‑DRB1 associations. Challenge: keeping entries up‑to‑date with rapidly emerging data.
OPAL – Outcome‑Based Patient‑Centric Autoimmune Ledger #
Quality metric, longitudinal tracking. System that records patient‑reported outcomes alongside clinical parameters to assess therapy effectiveness. Example: tracking fatigue scores in systemic sclerosis. Challenge: integrating data across multiple care sites.
PAD – Primary Antibody Deficiency #
Immunodeficiency, autoimmunity overlap. Disorders where low immunoglobulin levels coexist with autoimmune phenomena, such as CVID. Practical application: immunoglobulin replacement reduces infection and may modulate autoimmunity. Challenge: differentiating primary deficiency from secondary drug‑induced hypogammaglobulinemia.
PBMC – Peripheral Blood Mononuclear Cell #
Research sample, immunophenotyping. Blood fraction containing lymphocytes and monocytes used for flow cytometry in autoimmune studies. Practical application: assessing CD4⁺CD25⁺FOXP3⁺ regulatory T‑cells in patients on biologics. Challenge: variability in isolation techniques affecting reproducibility.
PCOS – Polycystic Ovary Syndrome #
Endocrine disorder, autoimmune component. Condition often associated with low‑grade inflammation and autoantibodies. Example: anti‑thyroid antibodies common in PCOS patients. Challenge: distinguishing metabolic from autoimmune contributions to symptom burden.
PEARL – Patient‑Engaged Autoimmune Research Liaison #
Advocacy, co‑creation. Program pairing patients with researchers to shape study design. Practical application: ensuring trial endpoints reflect patient‑valued outcomes like fatigue. Challenge: balancing scientific rigor with lay perspectives.
PFAPA – Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis #
Autoinflammatory syndrome, pediatric. Recurrent febrile episodes with mucosal involvement; some cases evolve into chronic autoimmune disease. Practical application: corticosteroid abortive therapy. Challenge: lack of long‑term data on progression to systemic autoimmunity.
PLEX – Therapeutic Plasma Exchange #
Plasmapheresis, antibody removal. Procedure that removes circulating autoantibodies and immune complexes. Example: used in severe myasthenia gravis crisis. Challenge: temporary effect; requires repeat sessions and vascular access management.
POC – Point‑of‑Care testing #
Rapid diagnostics, bedside assay. Quick measurement of CRP or autoantibodies in clinic. Practical application: immediate assessment of disease flare in rheumatoid arthritis. Challenge: lower sensitivity compared to central laboratory methods.
PRISM – Patient‑Reported Index for Systemic Manifestations #
Survey tool, disease burden. Questionnaire capturing organ‑specific symptoms in systemic lupus. Example: used to monitor renal, cutaneous, and neurologic involvement. Challenge: patient fatigue leading to incomplete responses.
PTC – Pro‑Thrombotic Condition #
APS, antiphospholipid antibodies. State of heightened clotting risk due to autoimmune mechanisms. Practical application: lifelong anticoagulation in high‑risk APS patients. Challenge: balancing bleeding risk, especially in surgery.
QALY – Quality‑Adjusted Life Year #
Health economics, outcome measure. Metric combining quantity and quality of life, used to assess cost‑effectiveness of autoimmune therapies. Example: calculating QALY gain from biologic versus conventional DMARD. Challenge: assigning utility values to subjective symptoms like fatigue.
RA – Rheumatoid Arthritis #
Synovial joint autoimmunity, erosive disease. Chronic inflammation leading to cartilage destruction and joint deformity. Practical application: early aggressive therapy with methotrexate and a biologic improves long‑term outcomes. Challenge: predicting which patients will develop extra‑articular manifestations.
RBC – Red Blood Cell #
Hemolysis, anemia of chronic disease. Target of autoantibodies in autoimmune hemolytic anemia. Example: Direct Coombs test confirms IgG‑mediated RBC destruction. Challenge: distinguishing immune hemolysis from drug‑induced hemolysis.
Rituximab – Anti‑CD20 monoclonal antibody #
B‑cell depletion, off‑label use. Used in rheumatoid arthritis, vasculitis, and certain glomerulonephritides. Practical application: weekly infusions for 4 weeks followed by maintenance dosing. Challenge: infusion reactions and prolonged B‑cell aplasia.
RNA‑seq – RNA sequencing #
Transcriptomics, gene expression profiling. High‑throughput method to identify dysregulated pathways in autoimmune tissues. Example: detecting interferon signatures in systemic lupus. Challenge: bioinformatic complexity and need for robust controls.
SAA – Serum Amyloid A #
Acute‑phase protein, amyloidosis precursor. Elevated during active inflammation; chronic elevation may lead to secondary amyloidosis in autoimmune patients. Example: monitoring SAA in long‑standing rheumatoid arthritis. Challenge: assay standardization across laboratories.
SCL‑70 – Anti‑Topoisomerase I Antibody #
Systemic sclerosis marker, diffuse disease. Autoantibody associated with severe pulmonary fibrosis. Practical application: positive SCL‑70 prompts early lung function surveillance. Challenge: false‑negative results in early disease.
SCID – Severe Combined Immunodeficiency #
Genetic immunodeficiency, autoimmunity risk. Rare condition where absent T‑ and B‑cell function predisposes to infections and occasional autoimmune phenomena. Practical application: hematopoietic stem cell transplant curative. Challenge: donor availability and graft‑versus‑host disease.
SELE – Selectin (E‑selectin) #
Endothelial adhesion molecule, leukocyte trafficking. Up‑regulated during inflammation; soluble E‑selectin levels correlate with disease activity in vasculitis. Practical application: biomarker for monitoring treatment response. Challenge: variability due to concurrent infections.
SLEDAI – Systemic Lupus Erythematosus Disease Activity Index #
Composite score, organ involvement. Numeric tool assessing 24 clinical and laboratory variables. Example: score >6 indicates active disease requiring escalation. Challenge: time‑consuming calculation in busy clinics.
SMAD – SMAD Family Proteins #
TGF‑β signaling, fibrosis pathway. Intracellular mediators implicated in organ fibrosis seen in systemic sclerosis. Practical application: targeting SMAD signaling to attenuate skin thickening. Challenge: pathway redundancy limits efficacy of single agents.
SNAP – Systemic Nonspecific Autoimmune Panel #
Broad serology, screening. Panel combining ANA, ENA, anti‑dsDNA, and antiphospholipid antibodies. Practical application: initial work‑up for unexplained multisystem symptoms. Challenge: high false‑positive rate leading to unnecessary referrals.
SOC – Standard of Care #
Guideline‑based treatment, evidence‑based practice. Baseline therapeutic approach against which new interventions are compared. Example: methotrexate plus folic acid is SOC for early rheumatoid arthritis. Challenge: evolving evidence may shift SOC rapidly.
SPM – Small‑Molecule Pharmacologic Modulator #
Oral therapy, targeted inhibition. Class of drugs such as JAK inhibitors that modulate intracellular signaling pathways. Practical application: oral tofacitinib for ulcerative colitis. Challenge: off‑target effects leading to lipid abnormalities and infection risk.
SS – Sjögren’s Syndrome #
Exocrine gland autoimmunity, dry eyes/mouth. Chronic condition characterized by lymphocytic infiltration of salivary and lacrimal glands. Practical application: pilocarpine to stimulate saliva production. Challenge: increased lymphoma risk requiring vigilant monitoring.
STAT – Signal Transducer and Activator of Transcription #
JAK‑STAT pathway, cytokine signaling. Transcription factors activated by cytokine receptors; dysregulated in many autoimmune diseases. Practical application: JAK inhibitors block STAT activation to reduce inflammation. Challenge: STAT redundancy may diminish therapeutic impact.
TH17 – T‑Helper 17 cell subset #
IL‑17 production, mucosal immunity. Promotes neutrophil recruitment and tissue inflammation; implicated in psoriasis and ankylosing spondylitis. Practical application: targeting IL‑23 to indirectly suppress TH17 activity. Challenge: balancing host defense against fungal pathogens.
TLR – Toll‑Like Receptor #
Pattern‑recognition receptor, innate immunity. Receptors that detect microbial components and endogenous danger signals; over‑activation contributes to autoimmunity. Example: TLR7 agonists exacerbate lupus in murine models. Challenge: designing selective inhibitors without compromising pathogen defense.
TPM – Therapeutic Patient Monitoring #
Drug level measurement, adherence check. Strategy to assess serum concentrations of immunosuppressants such as cyclosporine. Practical application: adjusting dose to maintain therapeutic window. Challenge: variability in absorption and metabolism among patients.
TRAF – TNF Receptor‑Associated Factor #
Signal adaptor, NF‑κB activation. Intracellular proteins that propagate TNF and IL‑1 signals; potential therapeutic targets. Practical application: experimental inhibitors aiming to disrupt TRAF6 signaling in rheumatoid arthritis. Challenge: early‑stage development with limited human data.
TSH – Thyroid‑Stimulating Hormone #
Endocrine regulator, autoimmune thyroid disease. Elevated in hypothyroidism often caused by Hashimoto’s thyroiditis. Practical application: levothyroxine replacement guided by TSH levels. Challenge: fluctuations due to non‑thyroidal illness syndrome.
UC – Ulcerative Colitis #
Colonic inflammatory disease, autoimmune component. Chronic mucosal inflammation limited to colon. Practical application: anti‑TNF biologics and oral tofacitinib for moderate‑to‑severe disease. Challenge: increased colorectal cancer risk with long‑standing inflammation.
UHR – Ultra‑High Risk #
Pre‑clinical autoimmunity, predictive cohort